[Coagulation disorders in prostatic carcinoma (author's transl)].

Area of Science:

• Oncology
• Hematology

Context:

• Prostatic carcinoma is a significant health concern.
• Coagulation disorders can complicate cancer treatment.

Purpose:

• To investigate the incidence and characteristics of coagulation disorders in patients with prostatic carcinoma.
• To evaluate the role of heparin in managing these coagulopathies.

Summary:

• 70 patients with prostatic carcinoma were analyzed for coagulation abnormalities.
• 24.3% of patients exhibited evidence of intravascular coagulation, often subclinical.
• Higher thromboplastic activity was noted in cancerous prostate tissue compared to normal tissue.
• Coagulation disorders were more prevalent in advanced and poorly differentiated carcinomas.
• Heparin demonstrated a key role in treating overt consumption coagulopathy and in prophylaxis against bleeding and thrombosis, even during estrogen therapy.

Impact:

• Highlights the significant association between prostatic carcinoma and coagulation disorders.
• Emphasizes the importance of monitoring and managing hemostatic disturbances in these patients.
• Suggests a prophylactic and therapeutic role for heparin in managing coagulation issues related to prostatic carcinoma and its treatment.